Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VBDEE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2024105206A1 22i-5657 1
|
|||||
| Synonyms |
22i-5657
Click to Show/Hide
|
|||||
| Organization |
VINCERX PHARMA GMBH
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.4
|
|||||
| Structure |
|
|||||
| Antibody Name |
TPP-5657
|
Antibody Info | Antigen Name |
Undisclosed
|
||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
103ᇷ nM
|
|||
| Method Description |
The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | NCI H929 cells | CVCL_1600 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
103ᇷ nM
|
|||
| Method Description |
The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | NCI H929 cells | CVCL_1600 | ||